Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible's licensee, Quoin Pharmaceuticals, Inc. (NASDAQ:QNRX) reported multiple positive developments for QRX003, which utilizes Skinvisible's Invisicare technology and its formulation for the ...
Skinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and ...
The Pharma Letter2d
Dermal pharmacology: challenges facing generic topical and transdermal drug development
This article explores the latest conversations around generic topical and transdermal drug delivery systems (TDS) in the US ...
ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India
LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical ...